Mallinckrodt PLC Company Profile (NYSE:MNK)

About Mallinckrodt PLC

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company's segments include Specialty Brands, Specialty Generics and Nuclear Imaging. Its Specialty Brands segment produces and markets branded pharmaceutical and biopharmaceutical products for autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies, and central nervous system drugs. Its Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its Nuclear Imaging segment manufactures and markets radiopharmaceuticals (nuclear medicine).

Industry, Sector and Symbol:

Sector: Medical
Industry: Drugs - Generic
Sub-Industry: N/A
Exchange: NYSE
Symbol: MNK
CUSIP:

Key Metrics:

Previous Close: $76.31
50 Day Moving Average: $76.94
200 Day Moving Average: $65.86
52-Week Range: $107,713,000.00 - $50.90
Trailing P/E Ratio: 14.39
Foreward P/E Ratio: 9.18
P/E Growth: 1.10
Market Cap: $8.22B
Outstanding Shares: 107,713,000
Beta: 1.52

Profitability:

Net Margins: 16.39%
Return on Equity: 17.78%
Return on Assets: 5.77%

Debt:

Debt-to-Equity Ratio: 1.21%
Current Ratio: 1.68%
Quick Ratio: 1.31%

Additional Links:

Companies Related to Mallinckrodt PLC:

Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (?)

Ratings Breakdown:	3 Hold Ratings, 14 Buy Ratings
Consensus Rating:	Buy (Score: 2.82)
Consensus Price Target:	$95.75 (25.48% upside)

Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)

Show:

Date	Firm	Action	Rating	Price Target
9/21/2016	Morgan Stanley	Reiterated Rating	Buy	$82.00
9/16/2016	Leerink Swann	Reiterated Rating	Outperform	$91.00 -> $92.00
9/7/2016	Piper Jaffray Cos.	Reiterated Rating	Overweight	$112.00 -> $105.00
8/31/2016	Deutsche Bank AG	Lower Price Target	Buy	$87.00 -> $84.00
8/29/2016	Mizuho	Reiterated Rating	Buy	$91.00
8/26/2016	Goldman Sachs Group Inc.	Reiterated Rating	Neutral	$83.00
8/25/2016	BMO Capital Markets	Reiterated Rating	Positive -> Outperform	$93.00
8/25/2016	Barclays PLC	Reiterated Rating	Overweight	$88.00
8/12/2016	Stifel Nicolaus	Initiated Coverage	Buy	$95.00
8/4/2016	Jefferies Group	Reiterated Rating	Buy	$85.00 -> $95.00
8/3/2016	JPMorgan Chase & Co.	Set Price Target	Hold	$85.00
8/3/2016	Guggenheim	Reiterated Rating	Buy	$98.00
6/10/2016	Wells Fargo & Co.	Reiterated Rating	Buy
5/4/2016	Oppenheimer Holdings Inc.	Reiterated Rating	Buy
3/16/2016	Northland Securities	Reiterated Rating	Buy	$95.00
2/2/2016	Nomura	Reiterated Rating	Neutral	$100.00
10/7/2015	Bank of America Corp.	Lower Price Target	Buy	$135.00 -> $131.00
1/30/2015	CRT Capital	Boost Price Target	Fairly Valued	$84.00 -> $97.00
10/1/2014	Buckingham Research	Boost Price Target	Buy	$107.00 -> $115.00

(Data available from 9/26/2014 forward)

Earnings History for Mallinckrodt PLC (NYSE:MNK)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/21/2016
8/2/2016	Q316	$2.00	$2.20	$920.35 million	$970.60 million	View	Listen
5/3/2016	Q216	$1.72	$2.01	$878.70 million	$918.00 million	View	Listen
2/2/2016	Q116	$1.77	$2.00	$888.33 million	$915.00 million	View	Listen
11/23/2015	Q415	$1.77	$1.84	$869.41 million	$882.40 million	View	Listen
8/4/2015	Q315	$1.82	$2.05	$983.81 million	$965.10 million	View	Listen
5/5/2015	Q215	$1.48	$1.72	$860.89 million	$909.90 million	View	Listen
2/3/2015	Q115	$1.55	$1.84	$880.12 million	$866.00 million	View	Listen
11/19/2014	Q414	$1.41	$1.68	$759.04 million	$789.00 million	View	Listen
8/7/2014	Q314	$0.87	$1.20	$278.80 million	$653.10 million	View	Listen
5/8/2014	Q214	$0.78	$0.95	$566.50 million	$557.80 million	View	Listen
2/6/2014	Q1	$0.66	$0.88	$539.24 million	$540.20 million	View	Listen
11/7/2013		$0.85	$1.02	$572.57 million	$552.20 million	View	Listen
8/9/2013	Q3 2013	$0.78	$0.49	$557.22 million	$570.00 million	View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)

Current Year EPS Consensus Estimate: $7.67 EPS
Next Year EPS Consensus Estimate: $8.31 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	10	$1.64	$1.87	$1.77
Q2 2016	9	$1.95	$2.09	$2.05
Q3 2016	3	$1.98	$2.14	$2.04
Q4 2016	3	$2.13	$2.19	$2.16
Q1 2017	1	$1.99	$1.99	$1.99
Q2 2017	1	$2.16	$2.16	$2.16
Q3 2017	1	$2.02	$2.02	$2.02
Q4 2017	1	$2.07	$2.07	$2.07

(Data provided by Zacks Investment Research)

Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Mallinckrodt PLC (NYSE:MNK)

Insider Ownership Percentage: 0.53%
Institutional Ownership Percentage: 94.74%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/10/2016	Hugh M O'neill	VP	Buy	1,653	$60.99	$100,816.47
5/10/2016	Matthew K Harbaugh	CFO	Buy	500	$59.37	$29,685.00
5/6/2016	Mark Trudeau	CEO	Buy	1,000	$56.02	$56,020.00
5/6/2016	Steven J Romano	VP	Buy	900	$56.00	$50,400.00
3/4/2016	Coleman N Lannum III	VP	Buy	2,600	$62.63	$162,838.00
2/26/2016	Meredith B Fischer	VP	Buy	1,400	$69.80	$97,720.00
2/12/2016	Coleman N Lannum III	VP	Buy	600	$59.66	$35,796.00
2/10/2016	Coleman N Lannum III	VP	Buy	1,300	$62.58	$81,354.00
2/9/2016	Matthew K. Harbaugh	CFO	Buy	1,300	$63.00	$81,900.00
2/8/2016	Coleman N. Lannum III	VP	Buy	800	$66.37	$53,096.00
12/22/2015	Coleman N Lannum III	SVP	Buy	500	$72.50	$36,250.00
12/11/2015	Terrance L Carlson	General Counsel	Buy	1,000	$69.10	$69,100.00
12/2/2015	Gary M. Phillips	VP	Buy	1,000	$72.17	$72,170.00
11/30/2015	Mark Trudeau	CEO	Buy	1,350	$65.89	$88,951.50
11/27/2015	Coleman N Lannum III	SVP	Buy	1,200	$66.86	$80,232.00
11/27/2015	Meredith B Fischer	VP	Buy	2,200	$66.93	$147,246.00
11/27/2015	Terrance L Carlson	General Counsel	Buy	1,000	$66.54	$66,540.00
8/25/2015	Hugh M O'neill	SVP	Buy	1,197	$83.52	$99,973.44
8/25/2015	Mark Trudeau	CEO	Buy	1,000	$83.08	$83,080.00
8/21/2015	Coleman N Lannum III	SVP	Buy	2,375	$88.52	$210,235.00
8/21/2015	Mark Trudeau	CEO	Buy	2,000	$88.45	$176,900.00
6/4/2015	Coleman N Lannum III	VP	Buy	1,300	$126.41	$164,333.00
6/2/2015	Matthew K Harbaugh	CFO	Sell	22,106	$128.64	$2,843,715.84
5/18/2015	Mario D Saltarelli	VP	Sell	4,580	$127.44	$583,675.20
5/13/2015	Don M Bailey	Director	Sell	51,417	$122.45	$6,296,011.65
5/11/2015	Sandra L Hatten	VP	Sell	2,024	$122.29	$247,514.96
4/13/2015	Don M Bailey	Director	Sell	40,000	$127.61	$5,104,400.00
3/13/2015	Don M Bailey	Director	Sell	40,000	$123.40	$4,936,000.00
2/13/2015	Don M Bailey	Director	Sell	33,891	$114.63	$3,884,925.33
2/2/2015	Mark Trudeau	CEO	Sell	11,925	$105.94	$1,263,334.50
1/9/2015	Mark Trudeau	CEO	Sell	15,720	$102.00	$1,603,440.00
12/22/2014	Peter G Edwards	VP	Sell	1,265	$99.69	$126,107.85
12/18/2014	Mark Trudeau	CEO	Sell	13,831	$93.59	$1,294,443.29
9/10/2014	Raymond J Furey	VP	Sell	5,441	$85.90	$467,381.90
9/8/2014	Don M Bailey	Director	Sell	221,177	$85.23	$18,850,915.71
9/5/2014	Raymond J Furey	VP	Sell	15,000	$85.47	$1,282,050.00
9/5/2014	Virgil D Thompson	Director	Sell	25,000	$83.76	$2,094,000.00
9/2/2014	Raymond J Furey	VP	Sell	10,303	$81.61	$840,827.83
8/29/2014	Raymond J Furey	VP	Sell	4,840	$80.90	$391,556.00
8/19/2014	Joseph A Zaccagnino	Director	Buy	3,000	$71.06	$213,180.00
8/13/2014	Paulson & Co Inc	Major Shareholder	Buy	132,100	$69.80	$9,220,580.00
8/12/2014	J Martin Carroll	Director	Buy	2,000	$69.24	$138,480.00
8/12/2014	Paulson & Co Inc	Major Shareholder	Buy	467,900	$68.78	$32,182,162.00
8/11/2014	Paulson & Co Inc	Major Shareholder	Buy	207,900	$69.70	$14,490,630.00
8/7/2014	Paulson & Co Inc	Major Shareholder	Buy	700,200	$70.15	$49,119,030.00
8/1/2014	Paulson & Co Inc	Major Shareholder	Buy	275,000	$69.60	$19,140,000.00
6/11/2014	Melvin D Booth	Director	Buy	4,000	$76.05	$304,200.00
5/9/2014	Paulson & Co Inc	major shareholder	Buy	786,207	$73.63	$57,888,421.41
2/3/2014	Mark Trudeau	CEO	Sell	14,890	$56.12	$835,626.80

(Data available from 1/1/2013 forward)

Latest Headlines for Mallinckrodt PLC (NYSE:MNK)

Date	Headline
	Mallinckrodt plc (NYSE:MNK) Ratings in Focus \| Stocks Daily - Stocks Daily (NYSE:MNK) www.stocksdaily.net - September 24 at 10:37 AM
	Mallinckrodt plc (NYSE:MNK) Ratings in Focus (NYSE:MNK) www.stocksdaily.net - September 23 at 5:48 PM
	Endo Int'l: New CEO "Has His Work Cut Out For Him" (NYSE:MNK) blogs.barrons.com - September 23 at 5:48 PM
	Earnings According to Analysts for Mallinckrodt plc (NYSE:MNK)? - Frisco Fastball (NYSE:MNK) friscofastball.com - September 23 at 10:53 AM
	Mallinckrodt rebuffs Praxair's challenge of INOMAX patents - Seeking Alpha (NYSE:MNK) seekingalpha.com - September 23 at 10:53 AM
	Validity of Mallinckrodt's INOMAX® Patent Claims Upheld (NYSE:MNK) www.publicnow.com - September 23 at 10:53 AM
	Commit To Buy Mallinckrodt At $45, Earn 12.2% Using Options (NYSE:MNK) www.nasdaq.com - September 21 at 10:19 AM
	Mallinckrodt plc (NYSE:MNK)’s Accounts Payable Is $125.4 (NYSE:MNK) www.realistinvestor.com - September 21 at 10:19 AM
	How Will Valeant’s Profitability Pan Out over the Long Term? (NYSE:MNK) marketrealist.com - September 20 at 11:22 AM
	Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 million (NYSE:MNK) www.publicnow.com - September 19 at 10:43 AM
	Mallinckrodt plc (NYSE:MNK) Price Forecast At $94.25 (NYSE:MNK) www.stocksdaily.net - September 18 at 10:33 AM
	Mallinckrodt plc (NYSE:MNK) Price Forecast At $94.25 - Stocks Daily (NYSE:MNK) www.stocksdaily.net - September 17 at 5:49 PM
	Leerink Boosts PT on Mallinckrodt (MNK) to $92; Lifts INOMax Expectations (NYSE:MNK) www.streetinsider.com - September 16 at 8:59 AM
	Mallinckrodt plc (NYSE:MNK): How Are Analysts Advising to Play This Stock? - Post News (NYSE:MNK) www.kentuckypostnews.com - September 14 at 6:17 PM
	Mallinckrodt plc (NYSE:MNK) Is Expected To Post EPS Of $2.19 (NYSE:MNK) www.realistinvestor.com - September 13 at 11:01 AM
	Mallinckrodt To Present At Morgan Stanley Global Conference; Webcast At 8:45 AM (NYSE:MNK) www.nasdaq.com - September 12 at 5:57 PM
	Analysts Place Mallinckrodt plc (NYSE:MNK) Under the Lens of the Microscope - Post News (NYSE:MNK) www.kentuckypostnews.com - September 12 at 10:51 AM
	HC Trending Hot Stocks= CIGNA Corporation (CI), Mallinckrodt PLC (NYSE:MNK) - share market updates (press release) (NYSE:MNK) sharemarketupdates.com - September 12 at 10:51 AM
	The Sell-side Consensus is in on Mallinckrodt plc (NYSE:MNK); Earnings & Target Updates - National Daily Press (NYSE:MNK) www.nationaldailypress.com - September 9 at 5:55 PM
	The Sell-side Consensus is in on Mallinckrodt plc (NYSE:MNK); Earnings & Target Updates (NYSE:MNK) www.nationaldailypress.com - September 9 at 10:53 AM
	Mallinckrodt (MNK) PT, Estimates Updated at Piper Jaffray Following Sale of Nuclear Business (NYSE:MNK) www.streetinsider.com - September 7 at 9:45 AM
	Mallinckrodt plc (NYSE:MNK) Is Expected To Post EPS Of $2.23 - RealistInvestor.com (NYSE:MNK) www.realistinvestor.com - September 6 at 6:17 PM
	Clinton Drug Plan No Threat to Innovators (NYSE:MNK) finance.yahoo.com - September 6 at 6:17 PM
	Mallinckrodt plc (NYSE:MNK) Is Expected To Post EPS Of $2.23 (NYSE:MNK) www.realistinvestor.com - September 4 at 5:36 PM
	What Do Analysts Think Of Mallinckrodt Plc (NYSE:MNK)? (NYSE:MNK) magseriesusa.net - September 1 at 9:19 AM
	Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products (NYSE:MNK) www.publicnow.com - September 1 at 9:19 AM
	Health Economic Data Following Orthopedic Surgery for OFIRMEV® (Acetaminophen) Injection Published in Advances in Therapy (NYSE:MNK) www.publicnow.com - September 1 at 9:19 AM
	Mallinckrodt completes purchase of regenerative medicine company (NYSE:MNK) www.bizjournals.com - September 1 at 9:19 AM
	Mallinckrodt (MNK) Stock Price Target Reduced at Deutsche Bank (NYSE:MNK) www.thestreet.com - August 31 at 11:05 AM
	What’s behind Mallinckrodt’s Stratatech Acquisition? (NYSE:MNK) marketrealist.com - August 30 at 6:11 PM
	How StrataGraft Could Benefit Mallinckrodt’s Hospital Portfolio (NYSE:MNK) marketrealist.com - August 30 at 6:11 PM
	Mallinckrodt PLC Valuation – August 2016 $MNK (NYSE:MNK) www.moderngraham.com - August 30 at 9:33 AM
	Ratings & Crowd Appeal on Mallinckrodt plc (NYSE:MNK) - Post News (NYSE:MNK) www.kentuckypostnews.com - August 29 at 10:46 AM
	Mallinckrodt PLC (NYSE:MNK), UnitedHealth Group Inc (NYSE:UNH) - NYSE Journal (press release) (NYSE:MNK) stockznews.com - August 26 at 5:59 PM
	Short Interest Drops 21.8% For MNK (NYSE:MNK) www.forbes.com - August 25 at 6:10 PM
	Mallinckrodt's Top Drug Could Go the Way of EpiPen (NYSE:MNK) realmoney.thestreet.com - August 25 at 11:20 AM
	Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny (NYSE:MNK) www.thestreet.com - August 25 at 11:20 AM
	Piper Jaffray Stays Bullish on Mallinckrodt (MNK), Lifts PT to $112 (NYSE:MNK) www.streetinsider.com - August 24 at 9:20 AM
	MALLINCKRODT PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial (NYSE:MNK) biz.yahoo.com - August 24 at 9:20 AM
	Mallinckrodt sells nuclear imaging business for $690 million (NYSE:MNK) www.marketwatch.com - August 24 at 9:20 AM
	Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million (NYSE:MNK) www.publicnow.com - August 24 at 9:20 AM
	Mallinckrodt to sell nuclear imaging business for $690 million (NYSE:MNK) www.bizjournals.com - August 24 at 9:20 AM
	[$$] Mallinckrodt to Sell Nuclear-Imaging Operations (NYSE:MNK) www.wsj.com - August 24 at 9:20 AM
	Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives … (NYSE:MNK) finance.yahoo.com - August 23 at 10:39 AM
	Mallinckrodt Says Switzerland Okays ECP For Reimbursement (NYSE:MNK) www.rttnews.com - August 23 at 10:39 AM
	Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home Affairs (NYSE:MNK) www.publicnow.com - August 23 at 10:39 AM
	Mallinckrodt To Present At Morgan Stanley Global Healthcare Conference (NYSE:MNK) www.publicnow.com - August 22 at 10:48 AM
	Analysts See Mallinckrodt plc (NYSE:MNK) Reporting EPS Of $2.32 (NYSE:MNK) www.realistinvestor.com - August 21 at 5:36 PM
	Mallinckrodt To Present At Wells Fargo Securities Healthcare Conference (NYSE:MNK) www.publicnow.com - August 19 at 9:16 AM
	Behind Horizon’s Price-to-Sales Valuation (NYSE:MNK) marketrealist.com - August 18 at 6:22 PM